Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACE Inhibition · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Conventional BP Control | ACTIVE_COMPARATOR | Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age. |
| Intensified BP Control | EXPERIMENTAL | Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age. |
| Name | Type | Description |
|---|---|---|
| ACE Inhibition | DRUG | ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects. |
| Intensified Blood Pressure Control | DRUG | Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed. |
| Add-on Angiotensin Receptor Blockade | DRUG | In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication. |
Inclusion Criteria: * Age 3-18 years * Moderate state of renal failure (creatinine clearance 15 - 75 ml / min / 1.73 m²) * Mean arterial blood pressure (ABPM) \> 50.percentile and/or antihypertensive treatment * Written informed consent Exclusion Criteria: * Age \<3 years or \>18 years at start o...
ACE Inhibition is a small molecule being studied for use in children with chronic renal failure and hypertension, including acquired and congenital kidney disease. It is currently in Phase 3 clinical development and is being investigated as a treatment to slow the progression of chronic renal failure in pediatric patients.
ACE Inhibition targets the angiotensin-converting enzyme (ACE), which plays a role in blood pressure regulation and kidney function. By inhibiting this enzyme, the drug aims to reduce blood pressure and potentially slow the progression of chronic renal failure in children with kidney disease.
ACE Inhibition is being developed by Baxter International Inc., a company publicly traded under the ticker symbol BAX. The company is conducting clinical research to evaluate the drug's safety and efficacy in pediatric patients with chronic renal failure and hypertension.
ACE Inhibition is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved for use. The Phase 3 trial has been completed, and the results will help determine whether the drug can be submitted for regulatory approval.
ACE Inhibition has one completed Phase 3 clinical trial, identified as NCT00221845. This trial, titled 'Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients,' enrolled 400 children aged 3 years and older across multiple countries in Europe and Turkey.
Yes, ACE Inhibition refers to the class of drugs known as ACE inhibitors, which block the angiotensin-converting enzyme. In this context, it is the investigational treatment being studied by Baxter International for pediatric chronic renal failure and hypertension, though the specific drug name is not disclosed.